A. Mark Fendrick

Prof. A. Mark Fendrick

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
AFA. Mark Fendrick
A. Mark Fendrick
AMArnold S. Monto
Arnold S. Monto
BNBrian Nightengale
Brian Nightengale
MSMatthew Sarnes
Matthew Sarnes
RESPIRATORY TRACT infection is the most common illness in humans. Largely because of the high attack rate, respiratory tract infections are associated with significant patient morbidity and related mortality. In developing countries, morbidity due to respiratory tract infections may be at least as severe as that in industrialized countries; for children younger than 5 years, these infections are the leading cause of death.1

14 July 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
PCPeter Cram
Peter Cram
AFA. Mark Fendrick
A. Mark Fendrick
JIJohn Inadomi
John Inadomi
MCMark E. Cowen
Mark E. Cowen
DCDaniel Carpenter
Daniel Carpenter
SVSandeep Vijan
Sandeep Vijan
PUBLIC HEALTH experts have struggled to find ways to increase participation in preventive health programs. Commonly used interventions have included health fairs, mass media campaigns, and distribution of educational materials.1 Despite these efforts, use of many established preventive measures remains suboptimal.

21 February 2008 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
FPFeng Pan
Feng Pan
MCMichael E. Chernew
Michael E. Chernew
AFA. Mark Fendrick
A. Mark Fendrick
The inverse correlation between the complexity of a drug regimen and medication adherence is well established. Fixed-dose combination (FDC) therapies are hypothesized to enhance compliance by decreasing the number of required pills. The objective of the study is to compare adherence of a FDC [Glucovance®, a FDC of metformin and glyburide] to a 2-pill regimen. Longitudinal data from a large claims database were used to assess adherence from January 1, 2000, to December 31, 2001. Propensity scoring methods were used to mitigate concerns related to non-random assignment of patients to treatments. The subjects of the study were individuals prescribed metformin or sulfonylurea or both before July 2000, who were prescribed both metformin and sulfonylurea concurrently (either separately or FDC) after August 2000. Adherence was measured by medication possession ratio; the proportion of days on which a patient had medication available. The FDC enhanced adherence rates by approximately 13% when compared to a 2-pill regimen. Compared to 2-pill therapy, a FDC resulted in important increases in patient adherence. Economic analyses are warranted to determine whether the clinical benefits attributable to the adherence gains are worth the incremental cost of a FDC.

25 January 1999 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
AFA. Mark Fendrick
A. Mark Fendrick
MCMichael E. Chernew
Michael E. Chernew
RHRichard A. Hirth
Richard A. Hirth
BBBernard S. Bloom
Bernard S. Bloom
RBRajesh R. Bandekar
Rajesh R. Bandekar
JSJames M. Scheiman
James M. Scheiman
EPIDEMIOLOGICAL investigations have demonstrated individuals infected with Helicobacter pylori to be at an increased risk for cancer of the gastric body and antrum.1,2 In response to these findings, the International Agency for Research on Cancer classified H pylori as a group 1 carcinogen in humans, raising the question whether population-based screening should be undertaken.3 To date, no controlled trials have demonstrated that H pylori eradication alters the risk of gastric cancer. Moreover, results from prospective studies that directly quantify the impact of H pylori eradication on the risk of cancer on low-risk individuals are decades away.

1 January 2009 in Osteopathic Medicine and Primary Care
Verified
Journal Article
Open access
PDF file
AFA. Mark Fendrick
A. Mark Fendrick
BGBruce P Greenberg
Bruce P Greenberg
This review is intended to provide physicians with an overview of the benefits and risks associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of their patients with mild-to-moderate osteoarthritis (OA). New information on the inflammatory component of OA and the cardiovascular (CV) risk associated with cyclooxygenase (COX)-2-specific inhibitors has prompted efforts to revise the current recommendations for the use of NSAIDs in the treatment of patients with OA. Clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing OA pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints. The theoretical advantage of COX-2-specific inhibitors in reducing gastrointestinal (GI) toxicity has been demonstrated by clinical studies. GI complications can be reduced by using lower NSAID doses for the shortest duration or with a concomitant proton-pump inhibitor. All prescription NSAIDs carry a black box warning regarding CV risks; these risks vary among the NSAIDs. While ibuprofen and diclofenac are associated with an increased CV risk, naproxen was associated with a neutral CV risk relative to placebo. Ibuprofen, but not naproxen, attenuates the antiplatelet effects of aspirin. An understanding of the risks and benefits is important when choosing an NSAID. An exhaustive search of the medical literature since 1990 was conducted using the words "ibuprofen," "naproxen," "COX-2-specific NSAIDs," "nonspecific NSAIDs," "low-dose aspirin," and "nonprescription dosage." Databases searched included MEDLINE, EMBASE, and SCISEARCH. This article provides primary care physicians with the information needed to assist them in making more informed decisions in managing patients experiencing mild-to-moderate OA pain.

1 October 2001 in Clinical Therapeutics
Verified
Journal Article
Closed access
AFA. Mark Fendrick
A. Mark Fendrick
SSSanjay Saint
Sanjay Saint
IBItzhak Brook
Itzhak Brook
MJMichael R. Jacobs
Michael R. Jacobs
SPStephen I I Pelton
Stephen I I Pelton
SSSanjay Sethi
Sanjay Sethi